Regulatory lessons from China's COVID-19 vaccines development and approval policies
Coronavirus disease 2019, responsible for a global pandemic, is caused by the severe acute respiratory syndrome coronavirus 2. Several vaccines have been developed and approved worldwide, particularly in China. As of Oct 17, 2021, four new coronavirus vaccines in China have been conditionally approv...
Saved in:
Main Authors: | Jingshu Yang (Author), Yue Yang (Author) |
---|---|
Format: | Book |
Published: |
Compuscript Ltd,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A review of approved COVID-19 vaccines
by: Amol Jamkhande, et al.
Published: (2021) -
The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics
by: Federico M. Goodsaid
Published: (2019) -
On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012) -
Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures
by: Nishimura T, et al.
Published: (2006) -
Early approval of COVID-19 vaccines: Pros and cons
by: Md Arifur Rahman, et al.
Published: (2021)